secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2025-09-08T23:59:59+00:00
Accession:  0001193125-25-197610
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapport RAP-219 Phase 2a positive: 85.2% achieved ≥30% LE reduction, 24% seizure freedom
--------------------------------------------------------------------------------

- 85.2% of patients achieved ≥30% reduction in long episodes (p<0.0001); median LE reduction 71%.
- 72% achieved ≥50% reduction in clinical seizures (p<0.0001); 24% seizure freedom; median reduction 77.8%.
- RAP-219 well tolerated: no SAEs; 78.5% of TEAEs mild; 10% discontinuation due to TEAEs.
- Company plans end-of-Phase 2 FDA meeting Q4 2025; Phase 3 pivotal trials expected Q3 2026.
- Additional programs: Phase 2 bipolar mania trial enrolling, topline H1 2027; diabetic neuropathic pain update later 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000119312525197610/0001193125-25-197610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000119312525197610/d919002d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-197610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer